IL273912B2 - Treatment of thalamocortical dysrhythmia - Google Patents

Treatment of thalamocortical dysrhythmia

Info

Publication number
IL273912B2
IL273912B2 IL273912A IL27391220A IL273912B2 IL 273912 B2 IL273912 B2 IL 273912B2 IL 273912 A IL273912 A IL 273912A IL 27391220 A IL27391220 A IL 27391220A IL 273912 B2 IL273912 B2 IL 273912B2
Authority
IL
Israel
Prior art keywords
ketamine
therapy
use according
tlves
tms
Prior art date
Application number
IL273912A
Other languages
English (en)
Hebrew (he)
Other versions
IL273912B1 (en
IL273912A (en
Original Assignee
Best Steven Richard Devore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Best Steven Richard Devore filed Critical Best Steven Richard Devore
Publication of IL273912A publication Critical patent/IL273912A/en
Publication of IL273912B1 publication Critical patent/IL273912B1/en
Publication of IL273912B2 publication Critical patent/IL273912B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/002—Magnetotherapy in combination with another treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M19/00—Local anaesthesia; Hypothermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36021—External stimulators, e.g. with patch electrodes for treatment of pain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
    • A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
    • A61N1/36014—External stimulators, e.g. with patch electrodes
    • A61N1/36025—External stimulators, e.g. with patch electrodes for treating a mental or cerebral condition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/006—Magnetotherapy specially adapted for a specific therapy for magnetic stimulation of nerve tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/004—Magnetotherapy specially adapted for a specific therapy
    • A61N2/008—Magnetotherapy specially adapted for a specific therapy for pain treatment or analgesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N2/00—Magnetotherapy
    • A61N2/02—Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A61M2021/0005—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus
    • A61M2021/0055—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis by the use of a particular sense, or stimulus with electric or electro-magnetic fields
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/04—Liquids
    • A61M2202/0468—Liquids non-physiological
    • A61M2202/048—Anaesthetics
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04C—ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT MACHINES FOR LIQUIDS; ROTARY-PISTON, OR OSCILLATING-PISTON, POSITIVE-DISPLACEMENT PUMPS
    • F04C2270/00—Control; Monitoring or safety arrangements
    • F04C2270/04—Force
    • F04C2270/042—Force radial
    • F04C2270/0421—Controlled or regulated

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Disabilities (AREA)
  • Social Psychology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Magnetic Treatment Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL273912A 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia IL273912B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261729625P 2012-11-25 2012-11-25
US13/826,250 US8974365B2 (en) 2012-11-25 2013-03-14 Treatment of thalamocortical dysrhythmia
PCT/US2013/071275 WO2014081948A1 (en) 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia

Publications (3)

Publication Number Publication Date
IL273912A IL273912A (en) 2020-05-31
IL273912B1 IL273912B1 (en) 2024-07-01
IL273912B2 true IL273912B2 (en) 2024-11-01

Family

ID=50773848

Family Applications (2)

Application Number Title Priority Date Filing Date
IL273912A IL273912B2 (en) 2012-11-25 2013-11-21 Treatment of thalamocortical dysrhythmia
IL238979A IL238979B (en) 2012-11-25 2015-05-21 Treatment of thalamocortic dysrhythmias

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL238979A IL238979B (en) 2012-11-25 2015-05-21 Treatment of thalamocortic dysrhythmias

Country Status (10)

Country Link
US (5) US8974365B2 (enExample)
EP (2) EP2922591B1 (enExample)
JP (5) JP2016501865A (enExample)
KR (5) KR20200117062A (enExample)
CN (1) CN104981265A (enExample)
CA (1) CA2896568C (enExample)
ES (1) ES2882619T3 (enExample)
IL (2) IL273912B2 (enExample)
MX (1) MX2015006444A (enExample)
WO (1) WO2014081948A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10155114B2 (en) * 2014-06-03 2018-12-18 Dirk De Ridder Systems and methods of treating a neurological disorder in a patient
US10118038B2 (en) * 2015-03-24 2018-11-06 Dirk De Ridder Methods of neuromodulation
US10201708B2 (en) 2014-10-29 2019-02-12 Dirk De Ridder Method of treating a neurological disorder using network stimulation
EP3416723A4 (en) * 2016-02-21 2019-07-17 Tech Innosphere Engineering Ltd. NONINVASIVE ELECTRICAL BRAIN STIMULATION SYSTEM
US10596378B2 (en) * 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
US9950189B1 (en) * 2016-10-20 2018-04-24 Neuro-Laser Foundation Inc. Treatment methodologies using light therapy
US10905897B2 (en) * 2016-10-20 2021-02-02 Neuro-Laser Foundation, Inc. Synergistic treatment methodologies using light therapy
US11723579B2 (en) 2017-09-19 2023-08-15 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement
MY197404A (en) * 2017-11-22 2023-06-16 Lin Chieh Hsin Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
US11717686B2 (en) 2017-12-04 2023-08-08 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to facilitate learning and performance
KR102099200B1 (ko) * 2017-12-18 2020-04-09 서울대학교산학협력단 뇌 자극 장치
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
US11478603B2 (en) 2017-12-31 2022-10-25 Neuroenhancement Lab, LLC Method and apparatus for neuroenhancement to enhance emotional response
US12280219B2 (en) 2017-12-31 2025-04-22 NeuroLight, Inc. Method and apparatus for neuroenhancement to enhance emotional response
US11364361B2 (en) 2018-04-20 2022-06-21 Neuroenhancement Lab, LLC System and method for inducing sleep by transplanting mental states
WO2020056418A1 (en) 2018-09-14 2020-03-19 Neuroenhancement Lab, LLC System and method of improving sleep
CN109481845B (zh) * 2018-12-28 2022-04-01 深圳先进技术研究院 一种作用于不同脑区的经颅磁刺激的方法和相关装置
CN110064117B (zh) * 2019-03-27 2021-06-01 佛山职业技术学院 一种基于呐喊声音的心理宣泄交互方法及装置
EP3951075B1 (en) 2019-03-28 2024-07-24 Sumitomo Construction Machinery Co., Ltd. Shovel and construction system
US11786694B2 (en) 2019-05-24 2023-10-17 NeuroLight, Inc. Device, method, and app for facilitating sleep
US12059565B1 (en) * 2019-12-19 2024-08-13 Washington University Methods and systems for modulating unconsciousness or anesthesia in a subject
CN113041501A (zh) * 2021-03-22 2021-06-29 东南大学 联合磁刺激系统靶向视觉皮层快速抗抑郁的方法
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression
ES2994763B2 (es) * 2023-07-25 2025-11-03 Nauta Technomedical Res S L Sistema de neuroestimulacion magnetica hiperbarica con ajuste parametrico semi automatico personalizable

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5084007A (en) * 1989-08-11 1992-01-28 Malin David H Method for chemical promotion of the effects of low current transcranial electrostimulation
US6132361A (en) * 1994-11-28 2000-10-17 Neotonus, Inc. Transcranial brain stimulation
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
US6176242B1 (en) * 1999-04-30 2001-01-23 Medtronic Inc Method of treating manic depression by brain infusion
US6591138B1 (en) * 2000-08-31 2003-07-08 Neuropace, Inc. Low frequency neurostimulator for the treatment of neurological disorders
US20110307029A1 (en) * 2008-08-06 2011-12-15 Cerephex Corporation Brain stimulation methods for treating central sensitivity
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
US8052591B2 (en) * 2006-05-05 2011-11-08 The Board Of Trustees Of The Leland Stanford Junior University Trajectory-based deep-brain stereotactic transcranial magnetic stimulation
CA2580694A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
US7613520B2 (en) * 2004-10-21 2009-11-03 Advanced Neuromodulation Systems, Inc. Spinal cord stimulation to treat auditory dysfunction
CN101686945A (zh) * 2004-11-23 2010-03-31 埃德莫斯药品有限公司 包含持续释放的包衣或基质和nmda受体拮抗剂的组合物，以及向受治疗者施用该nmda受体拮抗剂的方法
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US8676330B2 (en) * 2009-03-20 2014-03-18 ElectroCore, LLC Electrical and magnetic stimulators used to treat migraine/sinus headache and comorbid disorders
CN101432011A (zh) * 2006-02-27 2009-05-13 亚历山大·米哈洛 通过诱导逆适应调节神经递质系统的方法
US20100113959A1 (en) * 2006-03-07 2010-05-06 Beth Israel Deaconess Medical Center, Inc. Transcranial magnetic stimulation (tms) methods and apparatus
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
US7949403B2 (en) * 2007-02-27 2011-05-24 Accelerated Care Plus Corp. Electrical stimulation device and method for the treatment of neurological disorders
CA2722776A1 (en) * 2008-05-09 2009-11-12 Emory University Nmda receptor antagonists for the treatment of neuropsychiatric disorders
WO2010009141A1 (en) * 2008-07-14 2010-01-21 Arizona Board Of Regents For And On Behalf Of Arizona State University Methods and devices for modulating cellular activity using ultrasound
WO2010017249A1 (en) * 2008-08-04 2010-02-11 The Trustees Of Columbia University In The City Of New York Methods, apparatus and systems for magnetics stimulation
US8674095B2 (en) 2008-12-19 2014-03-18 Afraxis Holdings, Inc. Compounds for treating neuropsychiatric conditions
ES2672987T3 (es) * 2009-03-02 2018-06-19 Yeda Research And Development Co. Ltd. Esquema de configuración magnética y sincronización para la estimulación magnética transcraneal
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
CA2776770A1 (en) * 2009-10-09 2011-04-14 Afraxis, Inc. 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
KR20120107993A (ko) * 2009-12-15 2012-10-04 뉴롭, 인코포레이티드 신경계 장애의 치료를 위한 화합물
WO2011123548A2 (en) * 2010-04-02 2011-10-06 Neostim, Inc Neuromodulation of deep-brain targets by transcranial magnetic stimulation enhanced by transcranial direct current stimulation
US20140058189A1 (en) * 2012-02-20 2014-02-27 William F. Stubbeman Systems and methods using brain stimulation for treating disorders

Also Published As

Publication number Publication date
EP3915551A1 (en) 2021-12-01
CN104981265A (zh) 2015-10-14
KR20230141875A (ko) 2023-10-10
IL238979B (en) 2020-08-31
US20150165224A1 (en) 2015-06-18
US20210101015A1 (en) 2021-04-08
JP2019065021A (ja) 2019-04-25
KR20250046361A (ko) 2025-04-02
MX2015006444A (es) 2015-10-29
KR20200117062A (ko) 2020-10-13
IL273912B1 (en) 2024-07-01
JP2020180141A (ja) 2020-11-05
US20140148636A1 (en) 2014-05-29
KR20220132667A (ko) 2022-09-30
CA2896568C (en) 2025-06-17
HK1215687A1 (zh) 2016-09-09
CA2896568A1 (en) 2014-05-30
US8974365B2 (en) 2015-03-10
ES2882619T3 (es) 2021-12-02
EP2922591A1 (en) 2015-09-30
IL273912A (en) 2020-05-31
US20180001104A1 (en) 2018-01-04
US9649501B2 (en) 2017-05-16
EP2922591A4 (en) 2016-08-10
JP2025029043A (ja) 2025-03-05
JP2016501865A (ja) 2016-01-21
US10716950B2 (en) 2020-07-21
WO2014081948A1 (en) 2014-05-30
US20240207630A1 (en) 2024-06-27
KR20150091323A (ko) 2015-08-10
IL238979A0 (en) 2015-07-30
JP2022188221A (ja) 2022-12-20
EP2922591B1 (en) 2021-05-12

Similar Documents

Publication Publication Date Title
IL273912B2 (en) Treatment of thalamocortical dysrhythmia
Dedoncker et al. Combined transcranial direct current stimulation and psychological interventions: state of the art and promising perspectives for clinical psychology
Langguth et al. Tinnitus: therapeutic use of superficial brain stimulation
JP2016501865A5 (enExample)
Daskalakis et al. Repetitive transcranial magnetic stimulation for major depressive disorder: a review
Freire et al. Neurostimulation in anxiety disorders, post-traumatic stress disorder, and obsessive-compulsive disorder
Ambriz‐Tututi et al. Analgesic effect of repetitive transcranial magnetic stimulation (rTMS) in patients with chronic low back pain
JP2020180141A5 (enExample)
JP2015512418A5 (enExample)
BR112015027282A8 (pt) formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet
Du et al. Vagus nerve stimulation in cerebral stroke: biological mechanisms, therapeutic modalities, clinical applications, and future directions
JP2013155188A5 (enExample)
JP2015515985A5 (enExample)
RU2014150942A (ru) Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона
RU2012108656A (ru) Применение 4-аминопиридина для улучшения состояния при нейрокогнитивном и/или нейропсихиатрическом нарушении у пациентов с демиелинизирующими и другими заболеваниями нервной системы
Gliedt et al. Narrative review of perioperative acupuncture for clinicians
Antal et al. A case of refractory orofacial pain treated by transcranial direct current stimulation applied over hand motor area in combination with NMDA agonist drug intake
Cai et al. Clinical application of repetitive transcranial magnetic stimulation in improving functional impairments post-stroke: review of the current evidence and potential challenges
Knechtel et al. Transcranial direct current stimulation: neurophysiology and clinical applications
Gabis et al. Pain reduction using transcranial electrostimulation: a double blind" active placebo" controlled trial.
Mets et al. P. 1. i. 007 Positive effects of an energy drink on driving performance during prolonged driving
Kim et al. P. 1. i. 006 Clinical experience with electroconvulsive therapy at the university hospital in South Korea
CY1120669T1 (el) Συνδυαστικη θεραπεια για αγωγη σκληρυνσης κατα πλακας
Sanatkar et al. The small dose of ketamine prevents the hemodynamic disturbance in patients who underwent phacoemulsification with topical anesthesia and monitored anesthesia care
EL TRASTORNO et al. Neuroimaging and neurotherapeutics for attention deficit hyperactivity disorder (ADHD)